Side-by-Side Comparison
AOD-9604 vs Tesamorelin: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how AOD-9604 and Tesamorelin differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
AOD-9604
L2Also: Advanced Obesity Drug 9604, Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
A modified fragment of human growth hormone studied for fat metabolism without the growth-promoting effects of full GH.
Also: Egrifta, TH9507
An FDA-approved GHRH analog used for HIV-associated lipodystrophy, with research into broader metabolic and cognitive applications.
Side-by-side comparison
| Attribute | AOD-9604 | Tesamorelin |
|---|---|---|
| Primary mechanism | Lipolytic GH Fragment Activity | GHRH Receptor Agonism |
| FDA status | Research Only | FDA Approved |
| Evidence level | Preclinical Evidence | FDA Approved |
| Human trials | Yes (1+ indexed) | Yes (12+ indexed) |
| Studies indexed | 23 total (2 human, 14 animal) | 36 total (18 human, 8 animal) |
| Primary uses researched | Fat metabolism, Weight loss | Visceral fat reduction, HIV lipodystrophy, Cognitive function (research) |
| Administration routes | oral, subcutaneous | subcutaneous |
| Molecular weight | 1815.08 Da | 5135.93 Da |
| Amino acids | 16 | 44 |
| Category | weight loss | growth hormone |
| WADA status | Prohibited | Prohibited |
Key differences
Mechanism. AOD-9604 acts primarily through lipolytic gh fragment activity, while Tesamorelin acts primarily through ghrh receptor agonism. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. AOD-9604 is classified as research only; Tesamorelin is classified as fda approved. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. Tesamorelin sits at a higher evidence level (L5) than AOD-9604 (L2) under PeptideMark's L1–L5 methodology.
Research focus. Published research on AOD-9604 has concentrated on fat metabolism, weight loss. Research on Tesamorelin has concentrated on visceral fat reduction, hiv lipodystrophy, cognitive function (research). These research programs have limited overlap, and comparisons are most useful when readers are evaluating adjacent therapeutic goals.
Safety snapshot
| Attribute | AOD-9604 | Tesamorelin |
|---|---|---|
| Documented effects | 4 total | 9 total |
| Serious events | 0 | 0 |
| Common events | 1 | 5 |
| Black box warning | No | No |
| Contraindications | 3 listed | 4 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | Injection site reactions |
Strengths & limitations
AOD-9604
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Not FDA-approved for any indication — research use only
- Limited evidence base (L2)
- Few human trials — most data is preclinical
- Prohibited in competitive sport under WADA
Tesamorelin
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L5)
- Multiple human clinical trials (12+ indexed)
Limitations
- Prohibited in competitive sport under WADA
Representative studies
AOD-9604
A double blind placebo controlled study of the effects of AOD9604 in overweight and obese subjects
Stier H, et al. · Journal of Obesity & Weight Loss Therapy (2013)
AOD-9604 failed to produce statistically significant weight loss compared to placebo in a clinical trial.
AOD 9604 Promotes Cartilage Proliferation and Type II Collagen Synthesis in Osteoarthritic Chondrocytes
Wu X, Brown L, Kasran A, et al. · International Journal of Obesity (2007)
AOD 9604 increased type II collagen synthesis by 180% and cartilage proteoglycan content by 156% in human OA chondrocytes.
PubMed 17387518Tesamorelin
Tesamorelin, a Growth Hormone–Releasing Factor Analogue, Reduces Visceral Fat in HIV-Infected Patients
Falutz J, et al. · Annals of Internal Medicine (2007)
Tesamorelin reduced visceral adipose tissue by 15.4% compared to placebo, without worsening glucose tolerance.
PubMed 17909207REDUCE-1: Tesamorelin in HIV-Associated Lipodystrophy — A Randomized Controlled Trial
Grunfeld C, Thompson M, Brown SJ, et al. · AIDS (2006)
Tesamorelin reduced visceral AT by 18.3% versus 8.3% placebo (p<0.001); improvement sustained at 26 weeks post-treatment.
PubMed 16816556Frequently asked
What is the main difference between AOD-9604 and Tesamorelin?
AOD-9604 is a modified fragment of human growth hormone studied for fat metabolism without the growth-promoting effects of full gh. Its primary mechanism is lipolytic gh fragment activity. Tesamorelin is an fda-approved ghrh analog used for hiv-associated lipodystrophy, with research into broader metabolic and cognitive applications. Its primary mechanism is ghrh receptor agonism. The two differ in regulatory status (Research Only vs FDA Approved), strength of evidence (L2 vs L5), and the primary conditions for which each is researched.
Is AOD-9604 or Tesamorelin FDA approved?
AOD-9604: Not FDA-approved. Has GRAS (Generally Recognized as Safe) status as a food additive only. Not approved as a drug. Tesamorelin: FDA-approved in 2010 as Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
How does the evidence base compare?
AOD-9604 has 23 indexed studies (2 human, 14 animal) and is rated Preclinical Evidence. Tesamorelin has 36 indexed studies (18 human, 8 animal) and is rated FDA Approved. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can AOD-9604 and Tesamorelin be compared directly?
AOD-9604 and Tesamorelin come from different therapeutic categories (weight loss vs growth hormone), so direct clinical comparison is limited. Readers often compare them because of overlapping research interest, shared patient populations, or adjacent mechanisms — not because head-to-head trial data exists.
Are AOD-9604 and Tesamorelin commonly stacked together?
There is no widely documented stacking protocol combining AOD-9604 and Tesamorelin in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, AOD-9604 or Tesamorelin?
AOD-9604 has 4 documented side effects (0 serious). Tesamorelin has 9 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are AOD-9604 and Tesamorelin administered?
AOD-9604 is typically administered via oral or subcutaneous. Tesamorelin is typically administered via subcutaneous. Route differences affect onset, peak levels, and patient convenience.
Which is better, AOD-9604 or Tesamorelin?
"Better" depends on the therapeutic goal, regulatory context, and individual response. AOD-9604 is most researched for fat metabolism and weight loss; Tesamorelin is most researched for visceral fat reduction and hiv lipodystrophy. FDA status also matters: Research Only for AOD-9604 vs FDA Approved for Tesamorelin. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
AOD-9604 →
Full profile
Tesamorelin →